Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need. Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis of an expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates.

Discovers and develops unique products for human health, plant, and animal applications

Emergent Product Development (UK) Ltd. develops oral vaccines for typhoid, traveler's diarrhea, hepatitis B, and anthrax. It also develops vaccines for meningitis and another for streptococcal infections for infants. The company is a biotechnology company focused on harnessing the immune system to treat and prevent disease in areas of significant unmet clinical needs. It was founded in 1996 and is located in Wokingham, UK.

ABION, Inc. engages in the development of biopharmaceuticals for treating incurable diseases. Its products include protein, nucleic acid, and antibody therapeutics. The company was founded on April 16, 2007 and is headquartered in Seoul, South Korea.

Hunan Jindai Technology Development Co., Ltd., established on 2021-11-12, The business scope includes other unspecified manufacturing industries;plastic products(Except for the national plastic restriction order to restrict business)development,Production,Sales;Recycling of recycled plastic,Production,processing,Granulation and sales.starch sugar(including but not limited to glucose,maltose,fructose,high fructose,fructooligosaccharide,Trehalose,isomerized sugar,Crystalline maltose and other series of high-end starch sugar),Starch Sugar Alcohol,Production and sales of cane sugar;rice protein powder,rice protein peptide,Production and sales of biological enzyme preparations;food,Rice Purchase,Processing and sales;Import and export(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Cibus Genetics LLC is a biotechnology company. It develops products in agriculture and specialty chemicals. The company was founded by Peter Beetham in 2001 and is headquartered in San Diego, CA.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Prokarium is a biopharmaceutical company leading the oncology field of microbial immunotherapy The Company’s pipeline is designed to unlock a new generation of immuno-oncology therapeutics by re engineering evolution into a synthetic biology platform Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune driven, long lasting antitumor effects

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Inke Innovation (Xiamen) Technology Co., Ltd., established on 1989-12-14, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Medical equipment rental;Manufacturing of special equipment(Manufacture of licensed professional equipment not included);Special Equipment Repair;Sales of bio-based materials;Specialty Chemicals Sales(Free of Hazardous Chemicals);Biochemical product technology research and development;Engineering and Technology Research and Experimental Development;Natural science research and experimental development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Production of Class III Medical Devices;Class III medical device business;Production of Class II Medical Devices;Drug import and export;pharmaceutical production(Steamed Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines);Pharmaceutical commissioned production(Steamed Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines);Import and export;Technology Import and Export;Import and export agency.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Hunan Huisheng Biotechnology Co., Ltd., established on 2014-02-13, Business scope includes starch sugar(including but not limited to glucose,maltose,fructose,high fructose,fructooligosaccharide,Trehalose,isomerized sugar,Crystalline maltose and other series of high-end starch sugar),Starch Sugar Alcohol,Production and sales of cane sugar(Including import and export);rice protein powder,rice protein peptide,Production and sales of biological enzyme preparations(Including import and export);Grain Purchase,Processing and sales,Production and sales of rice and its by-products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Valigen NV offers genotyping and functional genomics. The company is headquartered in Newtown, PA.

Zhejiang Yufang Biotechnology Co., Ltd., established on 2021-03-03, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;R&D and application of cell technology(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:pharmaceutical production;Pharmaceutical commissioned production;Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

Nanjing Yufang Biotechnology Co., Ltd., established on 2020-11-12, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;R&D and application of cell technology(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Anhui Xinxing Drug Development Co., Ltd., established on 1998-04-30, Business scope includes general business items:medicine,pesticide,food formula,chemical industry,Medical equipment research and development,technology transfer,Information Consulting;one,Class II medical device,Chemical products and raw materials(Does not contain dangerous goods)promotion of;Import and export business operation(Exclusions prescribed or prohibited by the state).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Viterra Inc. was a Canadian grain handling business, the nation's largest grain handler, with its historic formative roots in prairie grain-handling cooperatives, among them the iconic Saskatchewan Wheat Pool. Viterra Inc grew into a global agri-business with operations in Canada, the United States, Australia, New Zealand and China. Viterra operated three distinct, inter-related businesses: Grain Handling & Marketing, Agri-Products and Processing, enabling it to generate earnings at various points on the food production chain from field to the table. Following its $6.1-billion acquisition by Glencore International, on 1 January 2013 Viterra Inc was merged with Glencore purchaser, 8115222 Canada Inc.